The story of the development of Venetoclax by Genentech and AbbVie began in Australia in the late 1980s. Venetoclax was based upon a discovery at the Walter+Eliza Hall Institute which identified the role of Bcl-2 in facilitating the survival of cancer cells.
Venetoclax is approved for patients with chronic lymphocytic leukaemia with clinical trials underway in targeting other forms of blood as well as breast cancers.
Yes, but is Myc in this story?
Phylogica announced the award of a NHMRC grant in December 2016 to support research into Myc inhibitors and FPPs with potentially synergistic drug cargoes - the 4 year funding supports Dual targeting of Myc and apoptosis pathways for improved blood cancer treatment outcomes. The award was granted to Phylogica's collaborators including the Olivia Newton John Cancer Research Institute and Walter+Eliza Hall Institute.
Dr Doug Fairlie from ONCRI commented that the funding will build upon 'exciting' data already obtained which shows synergy between Phylogica's compounds which target Myc and drugs that target pro-survival proteins in cancer such as Bcl-2 and Mcl-1.
PYC Price at posting:
3.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)